Evidence map›Paper›PMID 32083086›Full record

ReviewFrontiers in medicine2020

Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases.

Ting Zhang, Zhihong Yang, Praveen Kusumanchi, Sen Han, Suthat Liangpunsakul

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. MicroRNA-21 is a potential therapeutic agent targetingMolecular therapy. Nucleic acids · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Non-coding RNAs in alcohol-associated liver disease.Liver research (Beijing, China) · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ting ZhangDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
Zhihong YangDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
Praveen KusumanchiDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
Sen HanDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.
Indiana University School of MedicineIndiana University – Purdue University Indianapolis · US

Funding

Novel biomarkers as a clinical tool for excessive alcohol use screeningR01AA025208 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT, TU, WANZHU · 2016 to 2020
$1.7M
Sestrin3 in the pathogenesis of alcoholic and non-alcoholic fatty liver diseaseR01DK107682 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DONG, X. CHARLIE, LIANGPUNSAKUL, SUTHAT · 2016 to 2019
$1.4M
Immunological Profiles and prognostic outcomes in patients with alcoholic hepatitisU01AA026917 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2018 to 2022
$1.2M
Integrating LncRNA to Methionine Metabolism in Alcoholic Fatty LiverK01AA026385 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI YANG, ZHIHONG · 2018 to 2022
$807k
Novel animal models to study miRNA-mediated alcoholic liver diseaseUH2AA026903 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI LIANGPUNSAKUL, SUTHAT · 2018 to 2019
$447k
Serum Proteomic Profiles as Biomarkers of Abusive Alcohol ConsumptionI01CX000361 · VA · RLR VA MEDICAL CENTER · PI LIANGPUNSAKUL, SUTHAT · 2012 to 2025
–
CSRD VA I01 CX000361NIAAA NIH HHS K01 AA026385NIAAA NIH HHS R01 AA025208NIAAA NIH HHS U01 AA026917NIAAA NIH HHS UH2 AA026903NIDDK NIH HHS R01 DK107682
6 · The paper itself

Abstract

MicroRNAs are small non-coding RNAs that range in length from 18 to 24 nucleotides. As one of the most extensively studied microRNAs, microRNA-21 (miR-21) is highly expressed in many mammalian cell types. It regulates multiple biological functions such as proliferation, differentiation, migration, and apoptosis. In this review, we summarized the mechanism of miR-21 in the pathogenesis of various liver diseases. While it is clear that miR-21 plays an important role in different types of liver diseases, its use as a diagnostic marker for specific liver disease or its therapeutic implication are not ready for prime time due to significant variability and heterogeneity in the expression of miR-21 in different types of liver diseases depending on the studies. Additional studies to further define miR-21 functions and its mechanism in association with each type of chronic liver diseases are needed before we can translate the bedside observations into clinical settings.

Indexed as

alcohol liver disease (ALD)hepatocellular carcinomamiRNA-21non-alcoholic fatty liver diseaseviral hepatitis

Identifiers

PMID32083086
PMCPMC7005070
OpenAlexW3003482005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.